Core Viewpoint - Yinosh experienced a 4.93% increase in stock price on November 5, with a trading volume of 83.7251 million yuan, indicating a positive market response despite a net financing outflow [1] Financing Summary - On November 5, Yinosh had a financing buy-in of 3.1131 million yuan and a financing repayment of 9.9966 million yuan, resulting in a net financing outflow of 6.8835 million yuan [1] - As of November 5, the total financing and securities lending balance for Yinosh was 72.5176 million yuan, which represents 1.76% of its market capitalization, indicating a low financing balance compared to the past year [1] Securities Lending Summary - On November 5, Yinosh had no shares repaid or sold in securities lending, with a total lending balance of 0 shares, which is at a high level compared to the past year [1] Company Overview - Shanghai Yinosh Biotechnology Co., Ltd. was established on May 12, 2010, and is located in the China (Shanghai) Pilot Free Trade Zone [1] - The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.7881 million yuan, reflecting a year-on-year decrease of 111.14% [2] - Since its A-share listing, Yinosh has distributed a total of 45.1135 million yuan in dividends [2] Shareholder Information - As of September 30, 2025, Yinosh had 4,849 shareholders, a decrease of 9.97% from the previous period, with an average of 18,703 circulating shares per shareholder, an increase of 257.28% [2] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [2]
益诺思11月5日获融资买入311.31万元，融资余额7251.76万元